Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

Journal Browser

Autoimmune Skin Diseases: Innovations, Challenges, and Opportunities

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 20 April 2026 | Viewed by 5243

Share This Special Issue

Special Issue Editor

Dr. Shany Sherman

E-Mail Website
Guest Editor

Department of Dermatology, Rabin Medical Center, Petah Tikva 4941492, Israel
Interests: vitiligo; hidradenitis suppurativa; psoriasis; population-based studies; immunology of skin diseases

Special Issue Information

Dear Colleagues,

The advent of biologic therapies has transformed the management of common inflammatory skin diseases such as psoriasis, atopic dermatitis, and hidradenitis suppurativa, leading to significant changes in drug utilization. While these treatments have greatly improved patient outcomes, they also present challenges, including an increasing economic burden on healthcare systems. This Special Issue will explore these challenges while addressing specific shifts in healthcare access, such as hospitalization rates, physician visits, and the emergence of comorbid conditions. Additionally, we will examine novel approaches to photodermatoses, such as solar urticaria and collagen vascular diseases, driven by advances in research on immunopathogenesis. A key focus will also be placed on recent developments in targeted therapies for immunobullous disorders and graft-versus-host disease, opening up new avenues for precision medicine. By integrating research on disease mechanisms, innovative treatment strategies, and healthcare impacts, this Special Issue will foster conversations around optimizing patient care and resource allocation in autoimmune dermatology.

Dr. Shany Sherman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

healthcare utilization
inflammatory skin diseases
photodermatoses
collagen vascular disease
immunobullous disorders
graft-versus-host disease

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Other

9 pages, 192 KB

Open AccessArticle

Healthcare Service Utilization and Medication Use in 128,239 Children with Atopic Dermatitis in Israel—A Cross-Sectional Case-Control Study

by Naama Tova Cohen, Amit Iton-Schwartz, Doron Comaneshter and Yulia Valdman-Grinshpoun

J. Clin. Med. 2025, 14(18), 6402; https://doi.org/10.3390/jcm14186402 - 10 Sep 2025

Viewed by 781

Abstract

Background: Atopic dermatitis (AD) is a chronic inflammatory disease requiring topical and systemic treatments. This study examines healthcare service utilization and medication use in children with AD in a large healthcare organization during the year 2024. Methods: A cross-sectional case-control study was conducted comparing 128,239 children with AD to 128,239 matched controls regarding healthcare utilization and medication use. Multivariate analysis assessed differences between the groups. Results: Children with AD had increased healthcare utilization compared to the control group, with higher rates of visits to pediatricians, general practitioners, and dermatologists. A total of 144 children (0.11%) with AD were treated by immunosuppressive drugs, as compared to 78 children (0.06%) in the control group (OR 1.8, 95% CI 1.4–2.4, p-value < 0.001). A total of 410 children (0.32%) were treated with biologic drugs as compared to 12 children (0.01%) in the control group (OR 34.3, 95% CI 19.3–60.9, p-value < 0.001). A total of 34 children (0.03%) were treated with Janus kinase (JAK) inhibitors as compared to 2 children (0.002%) in the control group (OR 17, 95% CI 4.1–70.8, p-value < 0.001). Conclusions: Increased utilization of healthcare services was observed in pediatric patients with AD compared to the control group. As only a small proportion of the children with AD received immunosuppressants, biologic treatments, and JAK inhibitors, we suggest that the use of systemic medications should be strongly considered in pediatric patients with moderate to severe AD. Full article

(This article belongs to the Special Issue Autoimmune Skin Diseases: Innovations, Challenges, and Opportunities)

11 pages, 460 KB

Open AccessArticle

Type 1 Diabetes/Hidradenitis Suppurativa Comorbidity—A Population-Based Study

by Shany Sherman, Ron Slama, Danielle Bar, Yochai Schonmann, Arnon D. Cohen, Yossef H. Taieb, Daniel Mimouni, Alon Peretz and Hadar Duskin-Bitan

J. Clin. Med. 2025, 14(8), 2625; https://doi.org/10.3390/jcm14082625 - 11 Apr 2025

Viewed by 1281

Abstract

Background: Type 1 diabetes (T1D) and hidradenitis suppurativa (HS) share several metabolic and inflammatory dysfunctions. Prior studies of the potential link between the diseases either lacked validated T1D diagnoses or established only an indirect association. This study sought to determine the odds of HS developing in patients with a validated diagnosis of T1D and to characterize the clinical features of HS/T1D comorbidity. Methods: A population-based nested case-control study was conducted including patients with HS and controls matched 5:1 for age, sex, and primary care clinic. T1D was diagnosed using a specialized algorithm, achieving 90% accuracy. Diagnostic validity was confirmed by diabetes specialists who manually reviewed a random subset of the files. Unadjusted and adjusted odds ratios (OR/aOR) were calculated to determine the odds of incident HS in patients with T1D. Results: The study included 10,919 patients with HS and 53,314 controls. A history of T1D was associated with an elevated odds of new-onset HS (OR 1.80 95% CI (1.30–2.40), p < 0.001), even after adjusting for demographics and metabolic and autoimmune comorbidities (aORs > 1.7, p < 0.001). Patients with HS/T1D comorbidity had higher proportions of autoimmune conditions than patients with HS alone (p < 0.001) and a higher mean Charlson Comorbidity Index score than both patients with HS alone (3.5 vs. 0.9, p < 0.001) and T1D alone (3.5 vs. 2.2, p = 0.004). Conclusions: T1D is associated with higher odds of the subsequent development of HS. Awareness of HS/T1D comorbidity is recommended owing to the elevated burden of metabolic and autoimmune conditions. Full article

(This article belongs to the Special Issue Autoimmune Skin Diseases: Innovations, Challenges, and Opportunities)

► Show Figures

Figure 1

Other

Jump to: Research

16 pages, 1436 KB

Open AccessSystematic Review

Efficacy of Therapies for Solar Urticaria: A Systematic Review and Meta-Analysis

by Maya Engler Markowitz, Yehonatan Noyman, Israel Khanimov, Itay Zahavi, Batya Davidovici, Riad Kassem, Daniel Mimouni and Assi Levi

J. Clin. Med. 2025, 14(16), 5736; https://doi.org/10.3390/jcm14165736 - 13 Aug 2025

Viewed by 1589

Abstract

Background: Solar urticaria is a rare and disabling photodermatosis. Due to its low prevalence, most available data regarding treatment are derived from observational studies and case series, and a systematic evaluation of treatment efficacy is lacking. This systematic review and meta-analysis aims to assess therapeutic outcomes across treatment modalities in order to guide clinical care. Methods: We conducted a systematic literature search across PubMed, ScienceDirect, the Cochrane Library, and ClinicalTrials.gov. Studies reporting treatment outcomes in patients with solar urticaria were included. Pooled response rates were calculated for each treatment modality. Results: Out of 508 studies initially identified, 38 met the inclusion criteria. Antihistamines were evaluated in 21 studies (376 patients), with a pooled response rate (partial or complete) of 83.0% (95% CI, 70.4–91.1%) and a complete response rate of 7.7% (95% CI, 1.7–28.3%). Phototherapy was assessed in 11 studies (145 patients), showing a similar overall response (89.8%; 95% CI, 77.9–95.3%) but a higher complete response rate (39.8%; 95% CI, 18.3–66.1%). Omalizumab, evaluated in nine studies (76 patients), demonstrated the highest efficacy, with 93.2% (95% CI, 73.8–98.5%) achieving response and 68.4% (95% CI, 48.5–83.2%) complete remission. Limited data on IVIG, cyclosporine, and plasmapheresis suggested partial efficacy in selected refractory cases. Conclusions: This meta-analysis may support clinical decision-making by clinicians. A stepwise approach is suggested: high-dose H₁ antihistamines as first-line therapy, phototherapy as an alternative option in patients with access to treatment centers, and omalizumab for those with insufficient response. In refractory cases, additional options might be considered. Full article

(This article belongs to the Special Issue Autoimmune Skin Diseases: Innovations, Challenges, and Opportunities)

► Show Figures

Figure 1

17 pages, 921 KB

Open AccessSystematic Review

Bullous Pemphigoid as a Manifestation of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Report of a Novel Case

by Sapir Glazer Levavi, Moshe Yeshurun, Pia Raanani, Mor Frisch, Meital Oren-Shabtai, Lev Pavlovsky, Daniel Mimouni and Anna Aronovich

J. Clin. Med. 2025, 14(12), 4068; https://doi.org/10.3390/jcm14124068 - 9 Jun 2025

Cited by 1 | Viewed by 1179

Abstract

Background/Objective: Bullous Pemphigoid (BP) is a well-recognized autoimmune subepidermal blistering disease. However, its occurrence following allogeneic hematopoietic stem cell transplantation (HSCT) is extremely rare. The objective of this study is to systematically review the available data on BP following an allogeneic HSCT with focus on treatment options. Methods: A systematic review of studies evaluating BP following allogeneic HSCT, incorporating a highly treatment-resistant case from our graft-versus-host disease (GvHD) dermatology clinic, of a 47-year-old patient, notable as the only reported instance of BP following HSCT in a patient with chronic lymphocytic leukemia (CLL) that transformed into diffuse large B-cell lymphoma (DLBCL) and GvHD due to HSCT. The review yielded 15 publications that met the eligibility criteria. Including our case, a total of 16 cases were analyzed. Results: Nearly all patients (14/16) in this review had chronic GvHD due to their HSCT. Twelve patients were males, and six were of Japanese origin. The mean age for BP diagnosis was 38 years (a range of 5–67). On average, BP developed one year post-HSCT. The most common treatment for BP in these patients was prednisolone, with the majority experiencing complete resolution of symptoms. Conclusions: BP following HSCT is an exceptionally rare condition with an unclear underlying mechanism. Full article

(This article belongs to the Special Issue Autoimmune Skin Diseases: Innovations, Challenges, and Opportunities)

► Show Figures

Journal Menu

Journal Browser

Autoimmune Skin Diseases: Innovations, Challenges, and Opportunities

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (4 papers)

Research

Other

Further Information

Guidelines

MDPI Initiatives

Follow MDPI